Frequency of injection visits during three years of treatment with Ranibizumab and Aflibercept in patients with Neovascular age related macular degeneration

Trial Profile

Frequency of injection visits during three years of treatment with Ranibizumab and Aflibercept in patients with Neovascular age related macular degeneration

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2016 New trial record
    • 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top